Physician profile
Bruce K Baker
NPI 1518079722
$4,239.45
in general payments reported to CMS, 2019-2025
26 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $89.61 · 2021: $364 · 2022: $614 · 2023: $874 · 2024: $869 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.03 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $647.94 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $599.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $546.15 | 2021-2025 | |
| Abbvie INC. | $281.25 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $260.49 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $251.80 | 2020-2025 | Trintellix |
| Revance Therapeutics, INC. | $251.30 | 2025 | Daxxify |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.10 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $185.56 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $153.92 | 2021-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $132.75 | 2022-2023 | Spravato |
| Pfizer INC. | $132.01 | 2023-2025 | |
| Abbott Laboratories | $97.49 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.24 | 2022-2025 | Jardiance |
| Galderma Laboratories, L.P. | $73.19 | 2023-2025 | Dysport |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $63.74 | 2021-2022 | |
| Exact Sciences Corporation | $57.64 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $41.51 | 2025 | Voquezna |
| Dexcom, INC. | $34.06 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $31.00 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $20.73 | 2025 | Azmiro |
| Inspire Medical Systems, INC. | $20.21 | 2024 | Inspire |
| Vertex Pharmaceuticals Incorporated | $18.35 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.89 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.40 | 2024 | Quviviq |
| Linus Health, INC. | $15.78 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.